Targeting signaling pathways in prostate cancer: mechanisms and clinical trials

Y He, W Xu, YT Xiao, H Huang, D Gu… - Signal transduction and …, 2022 - nature.com
Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications

G Aurilio, A Cimadamore, R Mazzucchelli… - Cells, 2020 - mdpi.com
Around 80–90% of prostate cancer (PCa) cases are dependent on androgens at initial
diagnosis; hence, androgen ablation therapy directed toward a reduction in serum …

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer

K Raina, J Lu, Y Qian, M Altieri… - Proceedings of the …, 2016 - National Acad Sciences
Prostate cancer has the second highest incidence among cancers in men worldwide and is
the second leading cause of cancer deaths of men in the United States. Although androgen …

RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance

DT Miyamoto, Y Zheng, BS Wittner, RJ Lee, H Zhu… - Science, 2015 - science.org
Prostate cancer is initially responsive to androgen deprivation, but the effectiveness of
androgen receptor (AR) inhibitors in recurrent disease is variable. Biopsy of bone …

Second generation androgen receptor antagonists and challenges in prostate cancer treatment

Y Chen, Q Zhou, W Hankey, X Fang, F Yuan - Cell Death & Disease, 2022 - nature.com
Prostate cancer is a hormone-dependent malignancy, whose onset and progression are
closely related to the activity of the androgen receptor (AR) signaling pathway. Due to this …

The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer …

M Del Re, E Biasco, S Crucitta, L Derosa, E Rofi… - European urology, 2017 - Elsevier
Background The androgen receptor splice variant 7 (AR-V7) is associated with resistance to
hormonal therapy in castration-resistant prostate cancer (CRPC). Due to limitations of the …

Let's talk about placental sex, baby: understanding mechanisms that drive female-and male-specific fetal growth and developmental outcomes

AS Meakin, JSM Cuffe, JRT Darby, JL Morrison… - International journal of …, 2021 - mdpi.com
It is well understood that sex differences exist between females and males even before they
are born. These sex-dependent differences may contribute to altered growth and …

Transcriptional mediators of treatment resistance in lethal prostate cancer

MX He, MS Cuoco, J Crowdis, A Bosma-Moody… - Nature medicine, 2021 - nature.com
Metastatic castration-resistant prostate cancer is typically lethal, exhibiting intrinsic or
acquired resistance to second-generation androgen-targeting therapies and minimal …

ARv7 represses tumor-suppressor genes in castration-resistant prostate cancer

L Cato, J de Tribolet-Hardy, I Lee, JT Rottenberg… - Cancer cell, 2019 - cell.com
Androgen deprivation therapy for prostate cancer (PCa) benefits patients with early disease,
but becomes ineffective as PCa progresses to a castration-resistant state (CRPC). Initially …

Alternative splicing in prostate cancer

A Paschalis, A Sharp, JC Welti, A Neeb… - Nature reviews Clinical …, 2018 - nature.com
Androgen receptor (AR) splice variants (AR-Vs) have been implicated in the development
and progression of metastatic prostate cancer. AR-Vs are truncated isoforms of the AR, a …